Pillstats
Rx only · Injection, Powder, For Solution · Intravenous

Ceftazidime

Brands: Tazicef · Ceftazidime

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US7 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCJ01DD02
RxCUI (US)2191
US makers3 labelers
Packages7
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

4789551.4K1.9K2025 Q12025 Q22025 Q32025 Q42026 Q1
1.1K
Rx · 2026 Q1
7.8K
Units dispensed
-22%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Hospira, Inc.unknown3SUPPLYING
Sagent Pharmaceuticalsunknown2SUPPLYING
WG Critical Care, LLCunknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Nov 14, 2025
    RESOLVEDShortage resolved: Ceftazidime Injection (Hospira, Inc., a Pfizer Company)

    Ceftazidime Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Anti-Infective.

  • Nov 14, 2025
    SHORTAGEDrug shortage: Ceftazidime Injection (Hospira, Inc., a Pfizer Company)

    Ceftazidime Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Anti-Infective.